{"id":"crchum-mt-cocktail","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The CRCHUM-MT cocktail is an experimental combination therapy developed at Centre hospitalier de l'Université de Montréal that targets multiple pathways in cancer immunotherapy. While specific components are not fully disclosed in public literature, such cocktails typically combine checkpoint inhibitors, cytokine modulators, or other immunomodulatory agents to overcome resistance mechanisms and improve therapeutic efficacy in difficult-to-treat cancers.","oneSentence":"CRCHUM-MT is a multi-target immunotherapy cocktail designed to enhance anti-tumor immune responses through combined modulation of immune checkpoints and tumor microenvironment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:29:26.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic cancer (specific indications not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT02291666","phase":"PHASE4","title":"Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2015-04","conditions":"Type 2 Diabetes","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15120,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["omeprazole","Losec","caffeine","Wake-up","bupropion"],"phase":"marketed","status":"active","brandName":"CRCHUM-MT cocktail","genericName":"CRCHUM-MT cocktail","companyName":"Centre hospitalier de l'Université de Montréal (CHUM)","companyId":"centre-hospitalier-de-l-universit-de-montr-al-chum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CRCHUM-MT is a multi-target immunotherapy cocktail designed to enhance anti-tumor immune responses through combined modulation of immune checkpoints and tumor microenvironment. Used for Advanced or metastatic cancer (specific indications not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}